Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy

References

• Castro LNG, Dietrich J. Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neurooncol Pract. 2021;8(3):259–265.
   PubMed Web of Science ®Google Scholar
• Yoon JG, Smith D, Tirumani SH, et al. CAR T-Cell therapy: an update for radiologists. AJR Am J Roentgenol. 2021;217(6):1461–1474.
   PubMed Web of Science ®Google Scholar
• Winter SF, Vaios EJ, Dietrich J. Central nervous system injury from novel cancer immunotherapies. Curr Opin Neurol. 2020;33(6):723–735.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–971.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–1419.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(16):3943–3951.
   PubMed Web of Science ®Google Scholar
• Sadeqi Nezhad M, Yazdanifar M, Abdollahpour‐Alitappeh M, et al. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. Biotechnol Bioeng. 2021;118(10):3691–3705.
   PubMed Web of Science ®Google Scholar
• Neelapu SS. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334–1348.
   PubMed Web of Science ®Google Scholar
• Beuchat I, Danish H, Rubin DB, et al. EEG findings in CART T associated neurotoxicity: clinical and radiological correlations. Neuro-Oncology. 2021;15:15.
   Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:1–5.
   PubMed Web of Science ®Google Scholar
• Gust J, Ponce R, Liles WC, et al. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020;11:577027.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Lee DK, Stetler-Stevenson M, Cui YK, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Schuster SS, Chong EA, Nasta SD, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26):2545–2554.
   PubMed Web of Science ®Google Scholar
• Guha-Thakurta N, Wierda WG. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy. Neurology. 2018;91(18):843.
   PubMed Web of Science ®Google Scholar
• Torre M, Solomon IH, Sutherland CL, et al. Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. J Neuropathol Exp Neurol. 2018;77(10):877–882.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210–2221.
   PubMed Web of Science ®Google Scholar
• Gust J, Finney OC, Li D, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86(1):42–54.
   PubMed Web of Science ®Google Scholar
• Karschnia PJ, Forst DA, Arrillaga-Romany IC, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212–2221.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Siegel A, Holtzman NG, et al. Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma. Am J Hematol. 2020;95(6):E146–E148.
   PubMed Web of Science ®Google Scholar
• Holtzman Noa XH, Bentzen S, Kesari V, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology. 2021;23(1):112–121.
   PubMed Web of Science ®Google Scholar
• Ruff MW, Siegler EL, Kenderian SS. A concise review of neurologic complications associated with chimeric antigen receptor T-cell immunotherapy. Neurol Clin. 2020;38(4):953–963.
   PubMed Web of Science ®Google Scholar
• Shah NN, Johnson BD, Fenske TS, et al. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020;4(10):2119–2122.
   PubMed Web of Science ®Google Scholar
• Shen D, Song H, Xu X, et al. Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children. Pediatr Hematol Oncol. 2020;37(4):288–299.
   PubMed Web of Science ®Google Scholar
• Tan AP. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia. Pediatr Blood Cancer. 2020;67(11):e28635.
   PubMed Web of Science ®Google Scholar
• Wang M, Jain P, Chi TL, et al. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020;8(2):e001114.
   PubMed Web of Science ®Google Scholar
• Nair R, Drillet G, Lhomme F, et al. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica. 2021;106(5):1504–1506.
   PubMed Web of Science ®Google Scholar
• Wang LX, Yu XQ, Cao J, et al. Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient. Int J Hematol. 2021;114(3):408–412.
   PubMed Web of Science ®Google Scholar
• Turtle CH, Berger C, Hudecek M, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
   PubMed Web of Science ®Google Scholar
• Rice J, Nagle S, Randall J, et al. Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol. 2019;21(8):40.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. Vol. 128. No. 22; 2016. p. 1147–1147.
   Google Scholar
• Özütemiz C, Roshan SK, Kroll NJ, et al. Concomitant acute toxic leukoencephalopathy and posterior reversible encephalopathy syndrome. J Neuroimaging. 2018;28(5):535–541.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Azad S, Azad R. Differentiation of leptomeningeal and vascular enhancement on post-contrast FLAIR MRI sequence: role in early detection of infectious meningitis. J Clin Diagn Res. 2015;9(1):8–12.
   Google Scholar
• Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021;28(1):248–258.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Sahashi Y, Baba Y, et al. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci. 2020;415:116941.
   PubMed Web of Science ®Google Scholar
• Tan AP. CAR-T cell therapy-related neurotoxicity in pediatric acute lymphoblastic leukemia: spectrum of imaging findings. Pediatr Neurol. 2020;111:51–58.
   PubMed Web of Science ®Google Scholar
• Sabale Avinash B, Anil P, Kalirajan K, et al. Osmotic myelinolysis: does extrapontine myelinolysis precede central pontine myelinolysis? Report of two cases and review of literature. Indian J Radiol Imaging. 2015;25(2):177–183.
   PubMedGoogle Scholar
• Godinho MV, Pires CE, Hygino da Cruz LC. Hypoxic, toxic, and acquired metabolic encephalopathies at the emergency room: the role of magnetic resonance imaging. Semin Ultrasound CT MR. 2018;39(5):481–494.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Phadke RV, et al. Usefulness of various MRI sequences in the diagnosis of viral encephalitis. Acta Trop. 2010;116(3):206–211.
   PubMed Web of Science ®Google Scholar